Animal models of bipolar mania: The past, present and future
- PMID: 26314632
- PMCID: PMC4766066
- DOI: 10.1016/j.neuroscience.2015.08.041
Animal models of bipolar mania: The past, present and future
Abstract
Bipolar disorder (BD) is the sixth leading cause of disability in the world according to the World Health Organization and affects nearly six million (∼2.5% of the population) adults in the United State alone each year. BD is primarily characterized by mood cycling of depressive (e.g., helplessness, reduced energy and activity, and anhedonia) and manic (e.g., increased energy and hyperactivity, reduced need for sleep, impulsivity, reduced anxiety and depression), episodes. The following review describes several animal models of bipolar mania with a focus on more recent findings using genetically modified mice, including several with the potential of investigating the mechanisms underlying 'mood' cycling (or behavioral switching in rodents). We discuss whether each of these models satisfy criteria of validity (i.e., face, predictive, and construct), while highlighting their strengths and limitations. Animal models are helping to address critical questions related to pathophysiology of bipolar mania, in an effort to more clearly define necessary targets of first-line medications, lithium and valproic acid, and to discover novel mechanisms with the hope of developing more effective therapeutics. Future studies will leverage new technologies and strategies for integrating animal and human data to reveal important insights into the etiology, pathophysiology, and treatment of BD.
Keywords: animal models; bipolar disorder; circadian rhythms; genetics; mania; mood stabilizers.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.J Manag Care Pharm. 2006 May;12(4):322-30. doi: 10.18553/jmcp.2006.12.4.322. J Manag Care Pharm. 2006. PMID: 16792438 Free PMC article.
-
Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression.CNS Neurol Disord Drug Targets. 2015;14(8):963-9. doi: 10.2174/1871527314666150909115203. CNS Neurol Disord Drug Targets. 2015. PMID: 26350335 Review.
-
Efficacy of antimanic treatments in mixed states.Bipolar Disord. 2012 May;14 Suppl 2:22-36. doi: 10.1111/j.1399-5618.2012.00990.x. Bipolar Disord. 2012. PMID: 22510034 Review.
-
Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.Curr Drug Metab. 2018;19(8):663-673. doi: 10.2174/1389200219666171227203737. Curr Drug Metab. 2018. PMID: 29283064 Review.
Cited by
-
GWAS-identified bipolar disorder risk allele in the FADS1/2 gene region links mood episodes and unsaturated fatty acid metabolism in mutant mice.Mol Psychiatry. 2023 Jul;28(7):2848-2856. doi: 10.1038/s41380-023-01988-2. Epub 2023 Feb 21. Mol Psychiatry. 2023. PMID: 36806390 Free PMC article.
-
A Pattern to Link Adenosine Signaling, Circadian System, and Potential Final Common Pathway in the Pathogenesis of Major Depressive Disorder.Mol Neurobiol. 2022 Nov;59(11):6713-6723. doi: 10.1007/s12035-022-03001-3. Epub 2022 Aug 23. Mol Neurobiol. 2022. PMID: 35999325 Free PMC article. Review.
-
Genetic disruption of ankyrin-G in adult mouse forebrain causes cortical synapse alteration and behavior reminiscent of bipolar disorder.Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10479-10484. doi: 10.1073/pnas.1700689114. Epub 2017 Sep 11. Proc Natl Acad Sci U S A. 2017. PMID: 28894008 Free PMC article.
-
Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.Curr Neuropharmacol. 2017 Apr;15(3):424-433. doi: 10.2174/1570159X14666160902145635. Curr Neuropharmacol. 2017. PMID: 28503115 Free PMC article. Review.
-
The Brain Emotional Systems in Addictions: From Attachment to Dominance/Submission Systems.Front Hum Neurosci. 2021 Jan 15;14:609467. doi: 10.3389/fnhum.2020.609467. eCollection 2020. Front Hum Neurosci. 2021. PMID: 33519403 Free PMC article.
References
-
- Adida M, Clark L, Pomietto P, Kaladjian A, Besnier N, Azorin JM, Jeanningros R, Goodwin GM. Lack of insight may predict impaired decision making in manic patients. Bipolar Disord. 2008;10:829–837. - PubMed
-
- Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord. 2005;87:121–130. - PubMed
-
- Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH, Hutchins GD, Normandin MD, Yoder KK. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13:406–413. - PubMed
-
- Anand A, Darnell A, Miller HL, Berman RM, Cappiello A, Oren DA, Woods SW, Charney DS. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry. 1999;45:972–978. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous